StockData
Onconetix, Inc. logo

Onconetix, Inc. (ONCO) stock

ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$3.15+0.15 (+5.00%)

Close on Nov 18, 2026Market cap $12.44MP/E –Yield –

Onconetix operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Onconetix's operating income for the twelve months ending Jun 30, 2026 was -$16.31M. For fiscal 2025 it was -$17.86M. The highest annual figure on record is -$3.42M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$17.86M–
FY2024Dec 31, 2024-$56.49M–
FY2023Dec 31, 2023-$36.03M–
FY2022Dec 31, 2022-$13.48M–
FY2021Dec 31, 2021-$3.42M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.73M–
Q1 FY2026Mar 31, 2026-$10.23M–
Q4 FY2025Dec 31, 2025-$1.28M–
Q3 FY2025Sep 30, 2025-$2.07M–
Q2 FY2025Jun 30, 2025-$1.94M–
Q1 FY2025Mar 31, 2025-$12.57M–
Q4 FY2024Dec 31, 2024-$29.15M–
Q3 FY2024Sep 30, 2024-$2.65M–
Q2 FY2024Jun 30, 2024-$13.62M–
Q1 FY2024Mar 31, 2024-$11.08M–
Q4 FY2023Dec 31, 2023-$22.05M–
Q3 FY2023Sep 30, 2023-$4.49M–
Q4 FY2022Dec 31, 2022-$3.25M–
Q3 FY2022Sep 30, 2022-$3.87M–
Q2 FY2022Jun 30, 2022-$4.29M–
Q1 FY2022Mar 31, 2022-$2.07M–
Q4 FY2021Dec 31, 2021-$1.20M–
Q3 FY2021Sep 30, 2021-$1.10M–
Q2 FY2021Jun 30, 2021-$792.27K–
Q1 FY2021Mar 31, 2021-$325.78K–

More Onconetix figures

See a number that looks wrong?